U.S. accuses Novartis of transplant drug kickbacks

04/23/2013 | PharmaLive.com · Wall Street Journal, The

The U.S. Department of Justice has filed a lawsuit against the U.S. arm of Swiss firm Novartis alleging a kickback scheme using rebates and discounts to pharmacies to switch transplant patients to the company's Myfortic immunosuppressant treatment. By hiding these arrangements, "Novartis caused the public to pay tens of millions of dollars for kickback-tainted drugs that were dispensed by pharmacists" in partnership with the drugmaker, said U.S. Attorney Preet Bharara. Novartis is already subject to a five-year Corporate Integrity Agreement to resolve charges of improperly promoting its Trileptal epilepsy drug and several other medications. A representative for Novartis says it plans to dispute the new charges.

View Full Article in:

PharmaLive.com · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR